Trail Ridge Investment Advisors LLC Sells 123 Shares of Johnson & Johnson (NYSE:JNJ)

Trail Ridge Investment Advisors LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 1.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,353 shares of the company’s stock after selling 123 shares during the period. Trail Ridge Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,466,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of JNJ. WealthPlan Investment Management LLC grew its holdings in Johnson & Johnson by 495.4% during the 3rd quarter. WealthPlan Investment Management LLC now owns 67,728 shares of the company’s stock worth $10,549,000 after acquiring an additional 56,352 shares during the period. Van ECK Associates Corp grew its stake in shares of Johnson & Johnson by 5.7% in the 3rd quarter. Van ECK Associates Corp now owns 553,595 shares of the company’s stock valued at $86,222,000 after buying an additional 29,871 shares during the period. Platform Technology Partners grew its stake in shares of Johnson & Johnson by 5.7% in the 3rd quarter. Platform Technology Partners now owns 18,475 shares of the company’s stock valued at $2,877,000 after buying an additional 999 shares during the period. Plancorp LLC grew its stake in shares of Johnson & Johnson by 9.0% in the 3rd quarter. Plancorp LLC now owns 13,059 shares of the company’s stock valued at $2,034,000 after buying an additional 1,083 shares during the period. Finally, Tealwood Asset Management Inc. lifted its position in Johnson & Johnson by 2.0% in the 3rd quarter. Tealwood Asset Management Inc. now owns 15,565 shares of the company’s stock valued at $2,424,000 after acquiring an additional 312 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $0.33 during trading on Friday, hitting $145.12. The stock had a trading volume of 1,102,021 shares, compared to its average volume of 7,350,457. The firm has a market cap of $349.26 billion, a price-to-earnings ratio of 9.04, a P/E/G ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $175.97. The business’s 50-day moving average is $148.52 and its 200 day moving average is $154.71. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.68 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.42%. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JNJ. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. The Goldman Sachs Group began coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, June 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Monday. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and an average target price of $174.07.

Get Our Latest Stock Report on JNJ

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.